Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.44 |
| ▸ | ITK | Q08881 | 2/20 | 0.44 |
| ▸ | PLK4 | O00444 | 5/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | BLK | P51451 | 1/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.40 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | TYK2 | P29597 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17636837 | 0.92 | BTK (0.45) | BTKITKPLK4RIPK2ABL1 | |
| SCHEMBL17636845 | 0.91 | BTK (0.46) | BTKITKPLK4IGF1RRIPK2 | |
| SCHEMBL3376204 | 0.86 | IGF1R (0.47) | PLK4IGF1RABL1TDP1MAP2K4 | |
| SCHEMBL17636840 | 0.85 | BTK (0.41) | BTKITKPLK4RIPK2ABL1 | |
| SCHEMBL15805443 | 0.84 | BTK (0.62) | BTKITKPLK4IGF1R | |
| SCHEMBL17636843 | 0.83 | BTK (0.44) | BTKITKPLK4RIPK2ABL1 | |
| SCHEMBL12342935 | 0.83 | MAP4K1 (0.51) | BTKITKIGF1RABL1 | |
| SCHEMBL15799619 | 0.77 | BTK (0.63) | BTKITKPLK4IGF1R | |
| SCHEMBL12343233 | 0.77 | KCNH2 (0.46) | IGF1RABL1TDP1SCN9AGSK3A | |
| SCHEMBL17636849 | 0.77 | BTK (0.43) | BTKITKPLK4RIPK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951062-B2 | Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951062-B2 | Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160090382-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-03-31 | — | — | US | disclosed |
| US-20160090382-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090382-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | SIK2, SIK1, SIK3 | BTK 505/4885ITK 267/4885PLK4 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.